Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (2 quarters reported)
$109M in Q4 2025 → $52.8M now. Hover for any quarter.
As reported for the quarter ended March 31, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Evommune, Inc. | 55.8% | Unchanged | 1,280,778 | $29.4M |
| IS Inventiva S.a. | 24.8% | Trimmed 9.5% | 2,354,000 | $13.1M |
| Wave Life Sciences Ltd. | 10.3% | New | 750,000 | $5.44M |
| Rani Therapeutics Holdings, Inc. | 5.1% | Trimmed 42% | 3,667,585 | $2.69M |
| CN Clene Nanomedicine Inc. | 4.0% | Trimmed 44% | 431,094 | $2.13M |
| Surrozen, Inc. | 0.0% | Unchanged | 150,000 | $2.4K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 1 quarters.
quarter ended March 31, 2026 · filed May 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Verastem Inc | Exited | −2,000,000 | −$15.4M | — |
| Aldeyra Therapeutics Inc | Exited | −2,555,000 | −$13.2M | — |
| Precigen Inc | Exited | −3,000,000 | −$12.5M | — |
| Nuvation Bio Inc | Exited | −1,250,000 | −$11.2M | — |
| Aardvark Therapeutics, Inc. | Exited | −476,595 | −$6.26M | — |
| Wave Life Sciences Ltd. | New | +750,000 | +$5.44M | 10.3% |
| Generation Bio Co | Exited | −665,000 | −$3.78M | — |
| Rani Therapeutics Holdings, Inc. | Trimmed | −2,632,415 | −$1.93M | 5.1% |
| CN Clene Nanomedicine Inc. | Trimmed | −339,401 | −$1.67M | 4.0% |
| IS Inventiva S.a. | Trimmed | −246,000 | −$1.37M | 24.8% |
Loading...
